LA TERAPIA PER HBV ed HCV Cosa c è di nuovo?
|
|
- Blake Clarke
- 7 years ago
- Views:
Transcription
1 LA TERAPIA PER HBV ed HCV Cosa c è di nuovo? Alfredo Alberti Department of Molecular Medicine Molecular Hepatology Unit Venetian Institute of Molecular Medicine University of Padova ITALY
2 THERAPY OF HBV and HCV CHRONIC INFECTION two different strategies with an identical aim HBV : DISEASE CONTROL BY COMPLETE VIRUS SUPPRESSION WITH LONG-TERM ANTIVIRAL THERAPY HCV : DISEASE CONTROL BY VIRUS ERADICATION
3 THERAPY CHRONIC HEPATITIS B 2014 Option A : PEG-IFN (12 mo goal : immune control) depending on : Contraindications Patient s motivation Age ALT / Histologic activity HBV genotype (A and B better) Option B : NUCs Entecavir or Tenofovir (long-term virus suppression) Option C : PEG-IFN followed by NUC with PEG-IFN failure 3
4 Long-term with ETV or TDF therapy for CHB Viral suppression in >95% naïve/nuc-r patients ALT normalization in ~85% No major safety issues Fibrosis regression in >80% chronic hepatitis Fibrosis regression in >50% early cirrhotics Almost complete prevention of decompensation Reduction but no elimination of HCC risk
5 How Can We Cure Chronic HBV Infection? 2 Deplete or silence cccdna 1 Antiviral suppression 3 Reactivate disregulated antiviral Immunity HBV Virion ~10 ng/ml ~80% HBV Virion HBV Filament HBV Sphere HBV Virion ~10 ng/ml HBV HBV Virion Filament ~1 g/ml HBV Filament HBV Sphere ~100 g/ml HBV Sphere ~10 ng/ml ~10 ng/ml ~1 HBV g/ml Virion ~1 g/ml HBV ~100 Filament g/ml ~100 HBV g/ml Sphere ~80% HBV Virion HIGH ~10 ng/ml HBV ~85% HBV Virion Filament ~1 g/ml ~90% HBV Filament HBV HBsAg Sphere ~100 g/ml HBV Sphere COPY # ~80% HIGH ~80% HIGH ~10 ng/ml ~85% ~1 g/ml ~90% HBsAg ~10 ng/ml ~85% ~1 g/ml ~90% HBsAg ~100 g/ml ~100 g/ml COPY # COPY # ~80% HIGH MHBsAg LOW ~85% ~90% HBsAg HBV Virion COPY ~80% HIGH ~85% MHBsAg LOW HBV Filament ~80% # COPY # HIGH ~85% MHBsAg HBV Sphere HBsAg ~90% HBsAg LOW ~90% COPY # COPY # ~10 COPY ng/ml # COPY # ~1 g/ml LHBsAg HBV Virion HBV Filament ~5% HBV Sphere ~1% ~100 g/ml MHBsAg LOW ~5% LHBsAg HBV Virion HBV Filament HBV MHBsAg LOW Sphere ~1% HBV Virion LHBsAg ~10 ng/ml HBV Filament ~1 g/ml ~5% HBV COPY HBV Filament HBV Sphere Sphere # ~100 ~1% g/ml MHBsAg LOW ~5% ~1% LHBsAg ~10 ng/ml ~1 ~80% g/ml HIGH ~10 COPY ng/ml ~1 # g/ml ~100 ~85% g/ml COPY ~1 # g/ml ~100 ~90% g/ml HBsAg ~100 g/ml COPY # ~5% ~5% ~1% LHBsAg ~1% LHBsAg ~80% HIGH ~85% ~90% HBsAg COPY HIGH ~80% # HIGH ~85% ~90% HBsAg ~80% HIGH MHBsAg ~85% LOW ~90% HBsAg ~85% ~90% HBsAg COPY # COPY # COPY # COPY # MHBsAg LOW MHBsAg LOW LHBsAg HBV Virion COPY HBV Filament ~5% MHBsAg HBV MHBsAg LOW Sphere ~1% LOW # ~5% ~1% LHBsAg ~10 COPY ng/ml # COPY ~1 # g/ml COPY # ~100 g/ml ~5% ~5% ~1% LHBsAg ~5% ~1% LHBsAg ~1% LHBsAg ~80% HIGH COPY # LOW COPY # ~85% ~5% ~90% HBsAg ~1% PD-1 MHBsAg LHBsAg CD8 + T cell B cell 5
6 New HBV Treatments Virus Targeting New Nucleos(t)ide Analogues Entry inhibitors sirna antisense oligonucleotides cccdna silencing Immune Targeting TLR agonists Therapeutic vaccination PD-1, PDL-1 Blocking
7 COMBINATION OF ENTECAVIR plus PD-L1 BLOCKADE AND HBV VACCINE CHRONIC WHV MODEL Entecavir reduced PD-1 expression on CD8 T-cells Combination treatment resulted in enhanced T cell function and sustained immune control of WHV with definitive clearance of chronic infection Liu et al PLOS Pathogens 2014
8 THERAPY OF HCV IN THE LAST DECADE Lights and shadows of IFN PROOF OF CONCEPT HCV INFECTION CAN BE ERADICATED LIVER (AND EXTRA-HEPATIC) DISEASE CAN BE CURED HOWEVER MARGINAL EFFECT ON INFECTION AND DISEASE BURDEN DUE TO : - limited treatment of mild/asymptomatic cases - limited efficacy in advanced liver disease - many excluded due to side effects/contraindications
9 STAGES IN THE NATURAL HISTORY OF HCV Minimal Mild Moderate Severe Compensate cirrhosis F0 F1 F2 F3 F4 Decompensated Cirrhosis HCC Death HERAPY Defer Treat or Defer Treat Treatment contraindicated
10 THERAPY OF HCV the SOC HCV-2/3/4 DUAL PEG-IFN plus RIBAVIRIN for wks HCV-1 TRIPLE FIRST GENERATION PI (BOCEPREVIR/TELAPREVIR) plus PEG-IFN/RIBAVIRIN for wks SVR rates : 50-80% Many contraindications and side effects High drop-out rates Complex management High pill burden (up to 18/day 6300 total)
11 OUTCOMES WITH TRIPLE THERAPY OTTIMO 2013 ON THERAPY VIROLOGICAL RESPONSE 75% Data from 315 HCV-1 patients with F3-F4 SUSTAINED VIROLOGICAL RESPONSE DRUG RESISTANCE SEVERE RASH ANEMIA (< 10 g/dl) SEVERE ANEMIA (< 8 g/dl) EPO USED BLOOD TRANSFUSION REQUIRED PATIENTS HOSPITALISED 57% 25% 4.8% 39% 7% 33% 9% 6%
12 HCV Life Cycle and DAA Targets NS5A inhibitors Block replication complex formation, assembly Receptor binding and endocytosis Transport and release Translation and polyprotein processing Fusion and uncoating (+) RNA LD ER lumen LD Virion assembly NS3/4 protease inhibitors ER lumen Membranous web LD RNA replication NS5B polymerase RNA inhibitors replication Nucleoside/nucleotide Nonnucleoside Adapted from Manns MP, et al. Nat Rev Drug Discov. 2007;6:
13 NEW COMPOUNDS AVAILABLE IN 2014 SOFOSBUVIR SIMEPREVIR Polymerase (NS5B) inhibitor PI (second wave) inhibitor DACLATASVIR NS5A inhibitor 13
14 SOFOSBUVIR IFN FREE THERAPY IFN BASED THERAPY
15 SVR12 (%) SOFOSBUVIR FOR HCV-2 Treatment-Naïve Noncirrhotic Cirrhotic Treatment-Experienced 100% 98% 91% 92% 94% 97% 100% 96% 60% 91% 88% 100% 93% 80% 60% 40% 20% 0% 58/59 10/11 FISSION SOF + RBV 12 wk 85/92 16/17 POSITRON SOF + RBV 12 wk 29/30 2/2 VALENCE SOF + RBV 12 wk 25/26 6/10 FUSION SOF + RBV 12 wk 30/33 7/8 VALENCE SOF + RBV 12 wk 9/9 13/14 LONESTAR-2 SOF + PegIFN + RBV 12 wk Lawitz E, et al. N Engl J Med May 16;368(20): Zeuzem S, et al. AASLD Washington, DC. #1085. Jacobson IM, et al. N Engl J Med May 16;368(20):
16 Viral Response Rate (%) Pre-Transplant SOF + RBV to Prevent HCV Recurrence Post-Transplant Virologic Response 100 Post-Transplant Virologic Response /44* 25/39* Transplant PTVR 12 *3 subjects were >LLOQ at transplant. 1 subject has not reached ptvr12, 1 subject LTFU at Week 8 post transplant. SOF + RBV was effective and well-tolerated in patients with well compensated cirrhosis, and prevented post-transplant HCV recurrence in 64% of patients who had HCV RNA < 25 IU/mL prior to transplant Curry MP, et al. AASLD Washington, DC. Oral #213
17 Pre-Liver Transplant Study (SOF+RBV) No Recurrence (n=29) Recurrence (n=10) No recurrence in 24/25 (96%) of patients who maintained HCV RNA TND >28 days Median days TND No recurrence: 99 Recurrence: 5.5 p <0.001* 28 *Wilcoxon rank sum test. Curry MP, et al. APASL Brisbane, Australia. Oral presentation
18 IFN-Free DAAs COMBINATIONS NI + PI NI + NS5A PI + NS5A + / - Ribavirin NNI + PI +NS5A
19 Not All Direct-Acting Antivirals are Equal Characteristic Protease Inhibitor * Protease Inhibitor ** NS5A Inhibitor Nuc Polymerase Inhibitor Non-Nuc Polymerase Inhibitor Resistance profile Pangenotypic efficacy Antiviral potency Adverse events Good profile Average profile Least favorable profile Poordad F. and Dieterich D. J Viral Hepatitis 2012; 19: *First generation. **Second/third generation.
20 COSMOS: SVR12 with SOF (NI) plus SMV (PI) SVR12 (%) GT1b GT1a without Q80K GT1a with Q80K Cohort 1 (F0-F2 Nulls)* [1] Cohort 2 (F3-F4 Naives/Nulls)* [2] / 4 7/ 7 8/ 9 SMV/SOF + RBV 3/ 3 7/ 7 3/ 3 SMV/SOF 6/ 6 12/ 12 8/ 9 SMV/SOF+ RBV SMV/SOF SMV/SOF ± RBV 24 Wks 12 Wks Overall 4/ 4 4/ 4 5/ 6 7/ 17 30/ 30 24/ 27 6/ 6 11/ 11/ SMV/SOF + RBV 4/ 4 7/ 7 4/ 4 SMV/SOF 5/ 5 13/ 14 7/ 8 SMV/SOF + RBV SMV/SOF SMV/SOF ± RBV 24 Wks 12 Wks Overall 3/ 3 7/ 8 3/ 3 18/ 18 38/ 25/ *Excluding patients who discontinued for nonvirologic reasons. 1. Sulkowski M, et al. EASL Abstract O7. 2. Lawitz E, et al. EASL Abstract O165.
21 HCV RNA <LLOQ (% patients) All-oral daclatasvir(ns5a) plus sofosbuvir (NI) 100 Genotype 2/3 results Genotype 1 results Week 4 EOT B: SOF LI + DCV SVR4 SVR12 D: DCV + SOF F: DCV + SOF + RBV Missing SVR24 Week 4 EOT SVR4 SVR12 SVR24 A: SOF LI + DCV C: DCV + SOF E: DCV + SOF + RBV G: DCV + SOF (12-wk) H: DCV + SOF + RBV (12-wk) Adverse events Fatigue 29 50% Headache 16 38% Nausea 16 32% Sulkowski MS, et al. NEJM 2014 Virologic failures G1: Reinfection G3: 1 relapse (baseline A30K); 1 started IFN for LLQ-TD 3 pts missing from SVR4 in G and H were SVR 12 SVR12 in G and H 68/68 to date Ribavirin adds no benefit to SOF+DCV No safety signals Regimen needs evaluation in cirrhosis
22 Ledipasvir/Sofosbuvir: A Single Tablet Regimen (STR) Ledipasvir Picomolar potency against HCV GT 1a and 1b 1 Effective against NS5B RAV S282T 2 Once-daily, oral, 90 mg LDV NS5A inhibitor Sofosbuvir Potent antiviral activity against HCV GT 1 6 High barrier to resistance Once-daily, oral, 400-mg tablet Ledipasvir/Sofosbuvir STR Once-daily, oral fixed-dose (90/400 mg) combination tablet No food effect >2000 patients treated LDV NS5A inhibitor SOF - NS5B nucleotide polymerase inhibitor SOF - NS5B nucleotide polymerase inhibitor 1. Lawitz E, et al. EASL 2011, poster 1219; 2. Cheng G, et al. EASL 2012, poster 1172
23 SVR12 (%) ION Phase 3 Program (ION-1, ION-2, ION-3) Efficacy Summary SVR rates in different subgroups LDV/SOF LDV/SOF+RBV / / / / Weeks 24 Weeks 8 Weeks 12 Weeks 12 Weeks 24 Weeks ION-1 GT 1 treatment-naïve including cirrhotics ION-3 GT 1 treatment-naïve non-cirrhotic ION-2 GT 1 treatment-experienced including cirrhotics and PI failures 97% (1886/1952) overall SVR rate 3% (66/1952) did not achieve SVR 1.4% (28) LTFU 0.1% (2) virologic breakthrough (both due to non-adherence) 202/ % (36) relapsed. Patients may be rolled over to a retreatment study 201/ / / / / / 111
24 ION-2 (LDV/SOF±RBV x 12 or 24 weeks) LDV/SOF±RBV Safety Summary Patients, n (%) LDV/SOF n= Weeks 24 Weeks LDV/SOF+ RBV n=111 LDV/SOF n=109 LDV/SOF+ RBV n=111 AEs 73 (67) 96 (86) 88 (81) 100 (90) Grade 3 4 AEs 2 (2) 3 (3) 10 (9) 8 (7) Serious AEs (6) 3 (3) Treatment D/C due to AEs Death Grade 3 4 laboratory abnormality 5 (5) 15 (14) 9 (8) 27 (24) Hemoglobin <10 g/dl 0 2 (2) 0 9 (8) Hemoglobin <8.5 g/dl (2) Afdhal N, EASL, 2014, O109 Afdhal N, et al. N Engl J Med 2014; 2014 Apr 12 [Epub ahead of print]
25 ABBVIE 2D and 3D 2D ABT-450/r PI Ombitasvir NS5A inhibitor +/- RBV 3D ABT-450/r Ombitasvir Dasabuvir PI NS5A inhibitor NNI +/- RBV
26 ABT 450/r + ombitasvir + dasabuvir ± RBV SVR Rates in different groups 3D + RBV, 12 wk 3D RBV, 12 wk SAPPHIRE-I 1 Treatment-naive SAPPHIRE-II 2 Treatment-experienced PEARL-III 3 Treatment-naive, GT1b Increased incidence of pruritus observed with 3D regimen 1,2,3 High SVR rates achieved with 3D regimen despite baseline resistance-associated variants 4 3D = AbbVie triple combination; GT, genotype; RBV, ribavirin; SVR, sustained virologic response
27 Poordad et al EASL 2014
28 HCV -1 POST LIVER TRANSPLANT Kwo et al EASL 2014
29 MK-5172 (PI) + MK 8742 (NS5A) Phase 2 data HCV-1 naive/ non cirrhotics SVR % Hezode et al EASL 2014 HCV-1 naive /HIV coinfected SVR 90-97% Sulkowski et al EASL 2014 HCV-1 Cirrhotics/null SVR % Lawitz et al EASL 2014
30 FUTURE IMPACT OF IFN-FREE THERAPY Improved efficacy > 90% Extended eligibility > 90% VENETO Treated Predicted Efficient Disease Control Significant Economic Burden M Cost 150M
31 THE FUTURE OF HCV THERAPY All Oral Combinations with >90% cure More Efficacy/Safety data needed in advanced disease Costs will influence strategies Individual cure : a reality in few months Disease control : a possibility for many Countries in few years Global HCV eradication-the final goal : can it be achieved in few decades without a vaccine?
HCV Pipeline: The Next 18 Months Michael W. Fried, MD
HCV Pipeline: The Next 18 Months Michael W. Fried, MD Professor of Medicine Director, UNC Liver Center University of North Carolina at Chapel Hill Michael W. Fried, MD Commercial Disclosures Grants/Research
More informationEmerging Direct-Acting Antivirals for Treatment of Chronic Hepatitis C
Emerging Direct-Acting Antivirals for Treatment of Chronic Hepatitis C Debra Birnkrant, MD Director, DAVP DILI Conference March 20, 2013 1 HCV in the United States 3 to 4 million people have chronic HCV
More informationNew Research On Direct-acting Antivirals For The Treatment Of Hepatitis C
New Research On Direct-acting Antivirals For The Treatment Of Hepatitis C Highlights From EASL 214, London, U.K. This report contains highlights from a selection of abstracts and posters presented during
More informationHepatitis C: Eradication of a Disease? Gordon Dow, MD Oct 16 th, 2015
Hepatitis C: Eradication of a Disease? Gordon Dow, MD Oct 16 th, 2015 Disclosures: In the past two years I have participated in research 1 or received consultation/speaking fees 2 from: Astellas 2 Abbvie
More informationDebate: To Treat Now or Not to Treat Now. Age, Disease Stage, Resistance, and Comorbidities
Debate: To Treat Now or Not to Treat Now Age, Disease Stage, Resistance, and Comorbidities Moderator: Raymond T. Chung, MD Associate Professor of Medicine, Harvard Medical School Director of Hepatology
More informationHIV/Hepatitis C co-infection. Update on treatment Eoin Feeney
HIV/Hepatitis C co-infection Update on treatment Eoin Feeney HIV/Hepatitis C coinfection Where we are now Current treatment regimens and outcomes What s coming soon Direct acting antivirals (DAAs) What
More informationHCV in 2020: Any cases left? Rafael Esteban Hospital General Universitario Valle Hebron Barcelona. Spain
HCV in 2020: Any cases left? Rafael Esteban Hospital General Universitario Valle Hebron Barcelona. Spain Yes, still too many Measures to eradicate an Infectious Disease Prevention: Vaccination Screening
More informationObjectives. Hepatitis C: The new era of screening and treatment. Distribution of HCV genotypes 11/1/2014. History of HCV diagnosis and screening
Objectives Hepatitis C: The new era of screening and treatment David Crabb, M.D. Department of Medicine, Indiana University and Eskenazi Health Describe the natural history of HCV infection Be able to
More informationHepatitis Update. Study 110: SVR at post-treatment week 24 (SVR24) Jürgen Rockstroh, MD. No ART EFV/TDF/FTC ART/r/TDF/FTC Total
Hepatitis Update Jürgen Rockstroh, MD Study 11: SVR at post-treatment week 24 (SVR24) Patients with Undetectable HCV RNA (Percentage) 8 7 6 5 4 3 2 1 71 No ART EFV/TDF/FTC ART/r/TDF/FTC Total 69 8 74 n/n
More informationDE VERSCHILLENDE ANTIVIRALE MIDDELEN EN HUN WERKINGSMECHANISME
DE VERSCHILLENDE ANTIVIRALE MIDDELEN EN HUN WERKINGSMECHANISME Johan Neyts Rega Institute for Medical Research, University of Leuven, Belgium Johan.neyts@rega.kuleuven.be www.antivirals.be Pentalfa, 28
More informationClinical Criteria for Hepatitis C (HCV) Therapy
Diagnosis Clinical Criteria for Hepatitis C (HCV) Therapy Must have chronic hepatitis C (HCV infection > 6 months), genotype and sub-genotype specified to determine the length of therapy; Liver biopsy
More informationI. What s New and Updates/Changes (Last updated: February 17, 2015; last reviewed: February 17, 2015) Summary Table
Chronic Hepatitis C Virus (HCV) Infection: Treatment Considerations from the Department of Veterans Affairs National Hepatitis C Resource Center Program and the Office of Public Health Contents I. What
More informationRhinivirus - Cancer Treatment
16 th Annual Conference of the National HIV Nurses Association (NHIVNA) Susan Kidger North Manchester General Hospital 26-27 June 2014- City Hall, Cardiff 2 nd Generation Treatment for Hepatitis C and
More informationMEDICAL POLICY STATEMENT
MEDICAL POLICY STATEMENT Original Effective Date Next Annual Review Date Last Review / Revision Date 5/21/2014 3/24/2016 3/24/2015 Policy Name Policy Number Hepatitis C Oral SRx-0003 Medical Policy Statements
More informationUPDATE ON NEW HEPATITIS C MEDICINES
UPDATE ON NEW HEPATITIS C MEDICINES Diana Sylvestre, MD 2014 AASLD/IDSA Guidelines: Gt 1 Treatment naïve Interferon eligible: sofosuvir + ribavirin + PEG-IFN x 12 weeks Interferon ineligible: sofosbuvir
More informationRobert G. Knodell, M.D. Maryland Chapter, American College of Physicians Fb February 3, 2012
Treatment of Hepatitis C:Present and Future Robert G. Knodell, M.D. Scientific Meeting Maryland Chapter, American College of Physicians Fb February 3, 2012 Presentation Objectives Appreciate the Public
More informationMedical Policy An independent licensee of the Blue Cross Blue Shield Association
Hepatitis C Second Generation Antivirals (2015) Page 1 of 14 Medical Policy An independent licensee of the Blue Cross Blue Shield Association Title: See also: Hepatitis C Second Generation Antivirals Through
More informationHEPATITIS C. Current approach and Therapeutic considerations
HEPATITIS C Current approach and Therapeutic considerations Disease Burden Approximately 3.2 million people in the U.S. infected (1.3%) with HCV Responsible for 16,000 death per year in the U.S. (CDC 2010)
More informationA Cure is Within Reach:
A Cure is Within Reach: A Review of the New HCV Medications Misty Miller, Pharm.D., BCPS, AAHIVP Clinical Assistant Professor University of Oklahoma College of Pharmacy September 11, 2015 Pre Assessment
More informationHepatitis C Second Generation Antivirals (Harvoni, Technivie TM, Viekira Pak ) Prior Authorization - Through Preferred Agent(s) Program Summary
Hepatitis C Second Generation Antivirals (Harvoni, Technivie TM, Viekira Pak ) Prior Authorization - Through Preferred Agent(s) Program Summary This program applies to Health Insurance Marketplace, FlexRx
More informationPRIOR AUTHORIZATION PROTOCOL FOR HEPATITIS C TREATMENT
PRIOR AUTHORIZATION PROTOCOL FOR HEPATITIS C TREATMENT HARVONI (90mg ledipasvir/400mg sofosbuvir): tablet (PREFERRED AGENT) SOVALDI (sofosbuvir ): 400mg tablets (PREFERRED AGENT ) OLYSIO (simeprivir) PEG-INTRON
More informationPRIOR AUTHORIZATION POLICY
PRIOR AUTHORIZATION POLICY Harvoni (sofosbuvir/ledipasvir tablets Gilead) To initiate a Coverage Review, Call 1-800-417-1764 OVERVIEW Harvoni is a fixed-dose combination of ledipasvir, a hepatitis C virus
More informationPrevalenza HIV/HCV in Italia
Prevalence of HIV/HCV co-infection by region, 2013 WHO global systematic review of prevalence of HIV/HCV Ab co-infection based on prevalence studies in HIV+ persons stratified by risk group (where available)
More informationHEPATITIS C (HCV) CME ACCREDITED INTERACTIVE TRAINING SESSION: @DDW 2015
CME ACCREDITED INTERACTIVE TRAINING SESSION: HEPATITIS C (HCV) @DDW 2015 LIVER DISEASE 905 891 1900 www.careeducation.ca info@careeducation.ca Community Academic Research Education @wearecare CME ACCREDITED
More informationTreatment of Hepatitis C in Patients with Renal Insufficiency
HEPATITIS WEB STUDY HEPATITIS C ONLINE Treatment of Hepatitis C in Patients with Renal Insufficiency Robert G. Gish MD Professor Consultant, Stanford University Medical Center Senior Medical Director,
More informationTreatment of Chronic Hepatitis C - September 2014 Update
Treatment of Chronic Hepatitis C - September 014 Update Swiss Association for the Study of the Liver and Swiss Society for Infectious Diseases Written by: Darius Moradpour, Andri Rauch, Jan Fehr and Beat
More informationHepatitis C. Eliot Godofsky, MD University Hepatitis Center Bradenton, FL
Hepatitis C Eliot Godofsky, MD University Hepatitis Center Bradenton, FL Recent Advances in Hepatitis C Appreciation that many patients are undiagnosed Improved screening to identify infected persons Assessment
More informationCurrent Opinion in Hepatitis C Treatment
White Nights of Hepatology 2011 Current Opinion in Hepatitis C Treatment George V. Papatheodoridis, MD Associate Professor in Medicine & Gastroenterology 2nd Department of Internal Medicine, Athens University
More informationGUIDELINES FOR THE SCREENING, CARE AND TREATMENT OF PERSONS WITH CHRONIC HEPATITIS C INFECTION POLICY BRIEF
NEW RECOMMENDATIONS IN THE UPDATED WHO GUIDELINES FOR THE SCREENING, CARE AND TREATMENT OF PERSONS WITH CHRONIC HEPATITIS C INFECTION POLICY BRIEF NEW RECOMMENDATIONS IN THE UPDATED WHO GUIDELINES FOR
More informationA collaborative and agile pharmaceutical company with an R&D focus on infectious diseases and a leading position in hepatitis C
A collaborative and agile pharmaceutical company with an R&D focus on infectious diseases and a leading position in hepatitis C Q1-2013 Conference Call - Presenting team Maris Hartmanis, CEO Charlotte
More informationChronische Hepatitis C. 170 Millionen
Chronische Hepatitis C 170 Millionen Natürliche Geschichte der Hepatitis C Akute Hepatitis C Chronische Hepatitis C Hepatitis Zirrhose Clearance Zeit (20 Jahre) ist sehr unterschiedlich (Host, Virus, Umwelt)
More informationThe question and answer session is not available after the live webinar.
1 Read verbatim. 2 The Infectious Diseases Society of America (IDSA) Hepatitis C Knowledge Network offers monthly, 1 hour webinars to educate IDSA members on current recommended practices and treatments
More informationPost AASLD Update in HCV Torino, 10 Gennaio 2013. Fattori che possono influenzare il trattamento: RVR e Lead in
Post AASLD Update in HCV Torino, 10 Gennaio 2013 Fattori che possono influenzare il trattamento: RVR e Lead in Alessia Ciancio Università di Torino Città della Salute e delle Scienze Will predictors usefull
More informationMedical Policy An independent licensee of the Blue Cross Blue Shield Association
Hepatitis C Second Generation Antivirals Page 1 of 22 Medical Policy An independent licensee of the Blue Cross Blue Shield Association Title: Hepatitis C Second Generation Antivirals Through Preferred
More informationTherapy of decompensated cirrhosis Pre-transplant for HBV and HCV
Therapy of decompensated cirrhosis Pre-transplant for HBV and HCV Universitätsklinikum Leipzig Thomas Berg Sektion Hepatologie Klinik und Poliklinik für Gastroenterologie und Rheumatologie Leber- und Studienzentrum
More informationIn this study, the DCV+ASV regimen had low rates of discontinuation (5%) due to adverse events, and low rates of serious adverse events (5.
BMS Submits First All-Oral, Interferon-Free and Ribavirin-Free Treatment Regimen for Regulatory Review in Japan for Patients with Chronic Hepatitis C Infection An overall SVR 24 rate of 84.7 percent was
More informationCurrent & New Hepatitis C Meds on the Horizon
Current & New Hepatitis C Meds on the Horizon African Americans & Clinical Trials National Black Leadership Commission on AIDS May 28, 2014 Tracy Swan, Treatment Action Group Short for.. PEG-IFN pegylated
More informationPeg-IFN and ribavirin: what sustained virologic response can be achieved by using HCV genotyping and viral kinetics?
Peg-IFN and ribavirin: what sustained virologic response can be achieved by using HCV genotyping and viral kinetics? Prof. I. Bakulin Gastroenterology Department Key Questions Background Worldwide prevalence
More informationReview: How to work up your patient with Hepatitis C
Review: How to work up your patient with Hepatitis C You screened your patient, and now the HCV antibody test is positive. What do you do next? The antibody test only means they have been exposed to HCV.
More informationTreatment of Chronic Hepatitis C - September 2015 Update
Treatment of Chronic Hepatitis C - September 2015 Update Swiss Association for the Study of the Liver and Swiss Society for Infectious Diseases Written by: Beat Müllhaupt, Andri Rauch, Jan Fehr and Darius
More informationHIV/HCV Co-Infection
HIV/HCV Co-Infection 2015 Kentucky Conference on Viral Hepatitis Matt Cave, M.D. Associate Professor Department of Medicine Division of Gastroenterology, Hepatology, & Nutrition Department of Pharmacology
More informationNew treatment options for HCV: implications for the Optimal Use of HCV Assays
New treatment options for HCV: implications for the Optimal Use of HCV Assays Hans Orlent Dept. of Gastroenterology & Hepatology AZ Sint Jan Brugge-Oostende, Brugge This program is supported by educational
More informationboceprevir 200mg capsule (Victrelis ) Treatment naïve patients SMC No. (723/11) Merck Sharpe and Dohme Ltd
boceprevir 200mg capsule (Victrelis ) Treatment naïve patients SMC No. (723/11) Merck Sharpe and Dohme Ltd 09 September 2011 The Scottish Medicines Consortium (SMC) has completed its assessment of the
More informationLearning Objectives. HCV Treatment Evolution. Evolution of HCV Therapy 4/7/2014. Hepatitis C: A health problem of global importance!
Therapy New HCV In Frontiers We have no conflict of interest to declare. How the Magic Pill Cured Hep C Spring Therapeutics Update Trana Hussaini, Pharm D Nilu Partovi, Pharm D Google Images; collage by
More informationClinical Criteria for Hepatitis C (HCV) Therapy
Diagnosis Clinical Criteria for Hepatitis C (HCV) Therapy Must have chronic hepatitis C, genotype and sub-genotype specified to determine the length of therapy; Liver biopsy or other accepted test demonstrating
More informationLA TERAPIA PER HBV ed HCV Differenze di Genere? Alfredo Alberti. Dipartimento di Medicina Molecolare UOC Medicina Generale VIMM Università di Padova
LA TERAPIA PER HBV ed HCV Differenze di Genere? Alfredo Alberti Dipartimento di Medicina Molecolare UOC Medicina Generale VIMM Università di Padova HBV ed HCV Due virus Diversi ma con molte Cose in Comune
More informationCirrhosis and HCV. Jonathan Israel M.D.
Cirrhosis and HCV Jonathan Israel M.D. Outline Relationship of fibrosis and cirrhosisprevalence and epidemiology. Sequelae of cirrhosis Diagnosis of cirrhosis Effect of cirrhosis on efficacy of treatment
More informationPHARMACY PRIOR AUTHORIZATION
PHARMACY PRIOR AUTHORIZATION Hepatitis C Clinical Guideline Harvoni (sofosbuvir/ledipasvir), Sovaldi (sofosbuvir), Viekira PAK (ombitsavir, paritapravir/ritonavir, dasubavir), and Olysio (simeprevir) Authorization
More informationUpdate on Hepatitis C. Sally Williams MD
Update on Hepatitis C Sally Williams MD Hep C is Everywhere! Hepatitis C Magnitude of the Infection Probably 8 to 10 million people in the U.S. are infected with Hep C 30,000 new cases are diagnosed annually;
More informationHepatitis C Infection In Singapore
Hepatitis C Infection In Singapore Richard Guan MBBS, MRCP(UK), FAMS(Gastro), FRCP(Edin), FRCP(Lond) Gastroenterologist & Hepatologist, Mt Elizabeth Medical Centre, Singapore Summary of HCV treatment practice
More informationFocus on Transplantation: Treatment Post-transplant for HBV and HCV
Focus on Transplantation: Treatment Post-transplant for HBV and HCV The Viral Hepatitis Congress, Frankfurt, 09. September 2012 Christoph Sarrazin J. W. Goethe-University Hospital Medizinische Klinik I
More informationLedipasvir and Sofosbuvir for 8 or 12 Weeks for Chronic HCV without Cirrhosis
Ledipasvir and Sofosbuvir for 8 or 12 Weeks for Chronic HCV without Cirrhosis Massachusetts Medical Society, April 2014 sponsored by Gilead Sciences 23.04.2014 Marie-Luise Lauterjung 1 Zweck der Studie
More information17/01/14. What are special patient groups? Management of hepatitis C in special patient groups. Management of hepatitis C in
Management of hepatitis C in special patient groups Minisymposium Challenges in viral hepatitis 14 Lausanne 16.1.14 B. Müllhaupt Gastroenterology and Hepatology Swiss HPB- and Transplant-Center University
More informationHEPATITIS C UPDATE: A Quarter-Century Dramatic Journey. Steve T. Chen M.D. FACP, FACG
HEPATITIS C UPDATE: A Quarter-Century Dramatic Journey Steve T. Chen M.D. FACP, FACG Hepatitis C Virus: Morphology and Characteristics Hepatitis C Virus Discovered in 1989 Nucleic Acid: 9.6 kb ssrna 40-60
More informationHepatitis C Monitoring and Complications (and Treatment!) Dr Mark Douglas
Hepatitis C Monitoring and Complications (and Treatment!) Dr Mark Douglas Hepatitis C Virus Shimizu et al., 1996 Positive single strand RNA virus Flaviviridae family, Hepacivirus genus 9.6 kbp genome ~3000
More informationA 55 year old man with cirrhosis due to chronic hepatitis C (CHC) genotype 3a is referred for liver transplantation.
A 55 year old man with cirrhosis due to chronic hepatitis C (CHC) genotype 3a is referred for liver transplantation. Three years ago he was treated with 24 weeks of peginterferon alfa-2a (180 µg/wk, PEGIFN)
More informationTechnology appraisal guidance Published: 25 November 2015 nice.org.uk/guidance/ta364
Daclatasvir for treating chronic hepatitis C Technology appraisal guidance Published: 25 November 2015 nice.org.uk/guidance/ta364 NICE 2015. All rights reserved. Contents 1 Guidance... 3 Table 1 Daclatasvir
More informationHIV/HCV Co-infection. HIV/HCV Co-infection. Epidemiology. Dr Ranjababu Kulasegaram Guy s & St Thomas Hospital London. Extrahepatic manifestations
HIV/HCV Co-infection Dr Ranjababu Kulasegaram Guy s & St Thomas Hospital London HIV/HCV Co-infection Epidemiology Impact of HIV on HCV Epidemiology Impact of HCV on HIV Management issues Future Extrahepatic
More informationHEPATITIS C THERAPY PRIOR AUTHORIZATION FORM: Page 1 of 3 Patient Information. Diagnosis Acute Hep C Chronic Hep C Hepatocellular Carcinoma
HEPATITIS C THERAPY PRIOR AUTHORIZATION FORM: Page 1 of 3 Patient Information Recipient: MA#: Date of Birth: Phone #: Body Weight: Treatment Plan Sovaldi (sofosbuvir) 400mg: Take once daily for weeks Olysio
More informationManagement of HIV/HCV Co-infected Patients
Management of HIV/HCV Co-infected Patients David Wyles, MD Associate Professor of Medicine Division of Infectious Diseases University of California, San Diego San Diego, California Disclosures Grants/Research
More informationboceprevir 200mg capsule (Victrelis ) Treatment experienced patients SMC No. (722/11) Merck, Sharpe and Dohme Ltd
boceprevir 200mg capsule (Victrelis ) Treatment experienced patients SMC No. (722/11) Merck, Sharpe and Dohme Ltd 09 September 2011 The Scottish Medicines Consortium (SMC) has completed its assessment
More informationUnderstanding the Reimbursement Environment in Hepatitis C
Understanding the Reimbursement Environment in Hepatitis C Camilla S. Graham, MD, MPH, Division of Infectious Diseases, Beth Israel Deaconess Medical Center Robert Greenwald, JD, Clinical Professor of
More informationHepatitis C Glossary of Terms
Acute Hepatitis C A short-term illness that usually occurs within the first six months after someone is exposed to the hepatitis C virus (HCV). 1 Antibodies Proteins produced as part of the body s immune
More informationEfficacy of lead-in silibinin and subsequent triple therapy in difficult-to-treat HIV/hepatitis C coinfected patients
Second Silibinin Workshop, Cologne, 23 rd May 2014 Efficacy of lead-in silibinin and subsequent triple therapy in difficult-to-treat HIV/hepatitis C coinfected patients Dominique L Braun, MD Division of
More informationThe Comparative Clinical Effectiveness and Value of Simeprevir and Sofosbuvir in the Treatment of Chronic Hepatitis C Infection
The Comparative Clinical Effectiveness and Value of Simeprevir and Sofosbuvir in the Treatment of Chronic Hepatitis C Infection A Technology Assessment Final Report April 15, 2014 Completed by: Institute
More informationNo More Special Populations!?
No More Special Populations!? Mark Sulkowski, MD Professor of Medicine Johns Hopkins University School of Medicine Medical Director, Viral Hepatitis Center Divisions of Infectious Diseases and Gastroenterology/Hepatology
More informationUpdate on hepatitis C: treatment and care and future directions
Update on hepatitis C: treatment and care and future directions Professor Greg Dore Viral Hepatitis Clinical Research Program, National Centre in HIV Epidemiology and Clinical Research, University of New
More informationHepatitis C treatment update
Hepatitis C treatment update Viral Hepatitis Workshop Hepatitis Foundation and Regional Public Health December 2013 Jeffrey S Wong Hepatitis C treatment Non-A non-b hepatitis History of HCV treatment Hutt
More informationOptimising therapy in chronic hepatitis B: Switch or add treatment
Optimising therapy in chronic hepatitis B: Switch or add treatment Teerha Piratvisuth NKC Institute of Gastroenterology and Hepatology Prince of Songkla University,Thailand NA + NA Percent with resistance
More informationHIV and Hepatitis Co-infection. Martin Fisher Brighton and Sussex University Hospitals, UK
HIV and Hepatitis Co-infection Martin Fisher Brighton and Sussex University Hospitals, UK Useful References British HIV Association 2010 http://www.bhiva.org/documents/guidelines/hepbc/2010/ hiv_781.pdf
More informationLong-term Results of Pegylated Interferon alfa-2a and Tenofovir for Hepatitis B
Long-term Results of Pegylated Interferon alfa-2a and Tenofovir for Hepatitis B Patrick Marcellin Viral Hepatitis Research Center Hôpital Beaujon, University of Paris France OBJECTIVES OF THERAPY IN CHRONIC
More informationTechnology appraisal guidance Published: 25 November 2015 nice.org.uk/guidance/ta365
Ombitasvir paritaprevir ritonavir with or without dasabuvir for treating chronic hepatitis C Technology appraisal guidance Published: 25 November 2015 nice.org.uk/guidance/ta365 NICE 2015. All rights reserved.
More informationDaclatasvir for treating chronic hepatitis C
NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE Appraisal consultation document Daclatasvir for treating chronic hepatitis C The Department of Health has asked the National Institute for Health and Care
More informationHepatitis C Antiviral Therapy
MEDICAL POLICY POLICY RELATED POLICIES POLICY GUIDELINES DESCRIPTION SCOPE BENEFIT APPLICATION RATIONALE REFERENCES CODING APPENDIX HISTORY Hepatitis C Antiviral Therapy Number 5.01.606 Effective Date
More informationClinical case HIV HCV coinfection
Clinical case HIV HCV coinfection Dominique Salmon HUPC, Paris Descartes University PHC, January 2016 Disclosures Board of experts for Gilead and BMS Objectives To discuss: Results of DAA combination in
More informationObjectives. Disclosures 1/26/2016. Which of These Drugs is FDA Approved for the Treatment of Genotype 1 Infection?
New Horizons: Navigating the Changing Tides of Hepatitis C Therapy Jennifer Andres, PharmD, BCPS Clinical Assistant Professor of Pharmacy Practice Temple University School of Pharmacy Objectives Review
More informationNewton Kendig, MD RADM, Assistant Surgeon General, USPHS Assistant Director Health Services Division, FBOP
Newton Kendig, MD RADM, Assistant Surgeon General, USPHS Assistant Director Health Services Division, FBOP I do not have any relevant financial relationships with any commercial interests. At the end of
More informationTransmission of HCV in the United States (CDC estimate)
Transmission of HCV in the United States (CDC estimate) Past and Future US Incidence and Prevalence of HCV Infection Decline among IDUs Overall incidence Overall prevalence Infected 20+ years Armstrong
More informationAcute HCV was defined as (3 out of 4 within the preceding 4 months):
Christoph Boesecke, Patrick Ingiliz, Hans-Jürgen Stellbrink, Mark Nelson, Sanjay Bhagani, Marguerite Guiguet, Marc-Antoine Valantin, Thomas Reiberger, Martin Vogel, Jürgen K. Rockstroh, and the NEAT study
More informationSUN CITY. Exploring Current & Emerging Treatments for Chronic Hepatitis C (HCV): Cost & Effectiveness
Exploring Current & Emerging Treatments for Chronic Hepatitis C (HCV): Cost & Effectiveness David H. Winston, MD, FACP, AGAF Section Head, Gastroenterology & Hepatology CIGNA HealthCare of Arizona, Sun
More informationHEPATITIS COINFECTIONS
HEPATITIS COINFECTIONS Kenneth E. Sherman, MD, PhD Gould Professor of Medicine Director, Division of Digestive Diseases University of Cincinnati College of Medicine Disclosures (Activity w/i 12 months)
More informationHepatitis C in 2015. Primary Care Providers: Linkage to Care
Hepatitis C in 2015 Primary Care Providers: Linkage to Care Michael D Voigt Medical Director, Liver Failure and Transplantation University of Iowa, Hospitals and Clinics Disclosures I have NO disclosures
More informationNew IDSA/AASLD Guidelines for Hepatitis C
NORTHWEST AIDS EDUCATION AND TRAINING CENTER New IDSA/AASLD Guidelines for Hepatitis C John Scott, MD, MSc Associate Professor, UW SoM Asst Director, Liver Clinic, Harborview Medical Center Presentation
More informationSafety and Efficacy of DAA + PR in HCV/HIV co-infected patients. Mark Sulkowski, MD Johns Hopkins University Baltimore Maryland USA
Safety and Efficacy of DAA + PR in HCV/HIV co-infected patients Mark Sulkowski, MD Johns Hopkins University Baltimore Maryland USA Liver disease is the second leading cause of death amongst HIV-positive
More informationMedical publications on HBV and HCV Coinfection
Recent advances of HBV and HCV co-infection 台 中 榮 總 內 科 部 胃 腸 肝 膽 科 呂 宜 達 醫 師 2013.03.28 Outline Epidemiology of HBV and HCV coinfection Clinical significance of HBV and HCV coinfection Interplay between
More informationHepatitis Update. HCV Cure As A Paradigm for Convergence of Interests. Evidence Based Nuts and Bolts For the Family Doc 11/5/2014
Evidence Based Nuts and Bolts For the Family Doc Hepatitis Update William Carey MD MACG, FAASLD Oct 25, 2014 HCV Cure As A Paradigm for Convergence of Interests Hepatitis C Cure 1 Get Ready Get SET Go
More informationDATE: 16 January 2015 CONTEXT AND POLICY ISSUES
TITLE: Holkira (Ombitasvir/Paritaprevir/ Ritonavir with Dasabuvir) and Harvoni (Ledipasvir/Sofosbuvir) for Chronic Hepatitis C: A Review of the Clinical Evidence DATE: 16 January 2015 CONTEXT AND POLICY
More informationHCV Case Study. Optimizing Outcomes with Current Therapies
HCV Case Study Optimizing Outcomes with Current Therapies This program is supported by educational grants from Kadmon and Merck Pharmaceuticals. Program Disclosure This activity has been planned and implemented
More informationAn Approach to the Diagnosis and Treatment of Hepatitis C Virus Infection in 2015. Matthew McMahon, MD
An Approach to the Diagnosis and Treatment of Hepatitis C Virus Infection in 2015 Matthew McMahon, MD In the United States, 2.2-3.2 million people are infected with the hepatitis C virus (HCV) Half unaware
More informationA JOURNAL OF CURRENT TRENDS IN MEDICINE FROM IU HEALTH PHYSICIANS, A PARTNERSHIP OF IU SCHOOL OF MEDICINE AND INDIANA UNIVERSITY HEALTH
O C T O B E R 2 0 1 3 V O L. 1 3, I S S U E 4 ADVANCEDpraxis A JOURNAL OF CURRENT TRENDS IN MEDICINE FROM IU HEALTH PHYSICIANS, A PARTNERSHIP OF IU SCHOOL OF MEDICINE AND INDIANA UNIVERSITY HEALTH C A
More informationHepatitis C: Increasing Access and Improving Cure Rates
Hepatitis C: Increasing Access and Improving Cure Rates David Hachey, Pharm.D., AAHIVP Professor Idaho State University Department of Family Medicine 1 Disclosures The planners and presenter have disclosed
More informationBack to main HCV Drug Development Section. December 2012. By Tracy Swan
Submitted by tracyswan on Wed, 12/12/2012-20:09 Back to main HCV Drug Development Section December 2012 By Tracy Swan It is difficult to be anything other than dazzled by astounding cure rates of up to
More informationInnovazione farmacologica e farmacologia clinica
Innovazione farmacologica e farmacologia clinica Francesco Scaglione, MD, PhD Department of Medical Biotechnology and Translational Medicine School of medicine Postgradute School of clinical pharmacology
More informationNEW DRUGS FOR THE TREATMENT OF HEPATITIS C. Marcella Honkonen, PharmD, BCPS AzPA Annual Convention. Sunday, June 29 th, 2014 (1:15-2:15)
NEW DRUGS FOR THE TREATMENT OF HEPATITIS C Marcella Honkonen, PharmD, BCPS AzPA Annual Convention. Sunday, June 29 th, 2014 (1:15-2:15) Objectives Determine initial treatment options for patients with
More informationAll hepatitis C medications are specialty products; dispensing is available only via BriovaRx specialty pharmacy.
Hepatitis C Medications Prior Authorization Criteria Harvoni (ledipasvir/sofosbuvir), Sovaldi (sofosbuvir), Olysio (simeprevir) #, pegylated interferon (Pegasys & Peg-Intron ), Viekira Pak (ombitasvir/paritaprevir/ritonavir;
More informationWhy do I include peg-ifn in Hepatitis C treatment genotype 1
Why do I include peg-ifn in Hepatitis C treatment genotype 1 Ola Weiland Professor Karolinska Institute Karolinska University Hospital Huddinge Sweden My disclosures Participated in Advisory boards, served
More informationNew Hepatitis C Wonder Drugs: Who Is Worth the Cost?
New Hepatitis C Wonder Drugs: Who Is Worth the Cost? Riddle me this, riddle me that, your HCV treatment, who will pay for that? Rachel Rogers, PharmD PGY2 Infectious Diseases Pharmacy Resident South Texas
More informationCADTH THERAPEUTIC REVIEW Drugs for Chronic Hepatitis C Infection: Recommendations Report
CADTH THERAPEUTIC REVIEW Drugs for Chronic Hepatitis C Infection: Recommendations Report Product Line: Therapeutic Review Version: 1.0 Volume Number: 3 Issue Number: 1d Publication Date: November 2015
More informationRequest for Prior Authorization HEPATITIS C TREATMENTS
IA Medicaid Member ID # Patient name DOB FAX Completed Form To 1 (800) 574-2515 Provider Help Desk 1 (877) 776-1567 Patient address Patient phone Provider NPI Prescriber name Phone Prescriber address Fax
More information